QoL from TASCO1: health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy-Results from the TASCO1 phase II study
Moiseyenko, V Saunders, Mark P Wasan, HS Argiles, G Borg, C Creemers, GJ Fedyanin, M Glynne-Jones, R Pfeiffer, P Punt, CJA
Moiseyenko, V
Saunders, Mark P
Wasan, HS
Argiles, G
Borg, C
Creemers, GJ
Fedyanin, M
Glynne-Jones, R
Pfeiffer, P
Punt, CJA
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Moiseyenko V, Saunders MP, Wasan HS, Argiles G, Borg C, Creemers G-J, et al. QoL from TASCO1: health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy�Results from the TASCO1 phase II study. J Clin Oncol. 2019;37(4_suppl):676-.